EBMT 2023 | The current status of CAR-T therapy in second-line DLBCL in Europe
Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, comments on the current status of CAR-T therapy in the second-line treatment of diffuse large B-cell lymphoma (DLBCL) in Europe. Whilst CAR-T therapy is now available to patients in the second-line setting, access to these agents is heterogenous across different European countries due to reimbursement issues. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BELLICUM PHARMACEUTICALS: Membership on an entity’s Board of Directors or advisory committees
BMS/CELGENE: Speakers Bureau, Membership on an entity’s Board of Directors or advisory committees
EBMT: Membership on an entity’s Board of Directors or advisory committees
FRESENIUS KABI: Research Funding
KITE/GILEAD: Honoraria, Speakers Bureau, Membership on an entity’s Board of Directors or advisory committees
JANSSEN PHARMACEUTICALS: Membership on an entity’s Board of Directors or advisory committees
JAZZ: Honoraria
MILTENYI BIOTECH: Research Funding
NOVARTIS: Speakers Bureau
SANOFI SA: Speakers Bureau, Honoraria, Research Funding
TERUMO BCT: Speakers Bureau
